Analysts Offer Insights on Healthcare Companies: Acelrx (NASDAQ: ACRX), Celldex (NASDAQ: CLDX) and OncoSec Medical (NASDAQ: ONCS)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acelrx (NASDAQ: ACRX), Celldex (NASDAQ: CLDX) and OncoSec Medical (NASDAQ: ONCS) with bullish sentiments.

Acelrx (NASDAQ: ACRX)

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Acelrx (NASDAQ: ACRX). The company’s shares opened today at $3.20.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 12.6% and a 26.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics, Inc., and Sucampo Pharmaceuticals.

Acelrx has an analyst consensus of Strong Buy.

Celldex (NASDAQ: CLDX)

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Celldex (NASDAQ: CLDX) yesterday and set a price target of $9. The company’s shares opened today at $3.14, close to its 52-week low of $2.96.

Goldstein wrote:

“Adding Clinical-Stage Programs. With the acquisition of Kolltan, Celldex will add two clinical-stage programs to its portfolio, as well as a preclinical program. The candidates are receptor tyrosine kinases (RTKs), which are involved in signaling in a variety of cellular functions. Mutations and dis-regulation of RTKs have been implicated in disease, including cancer. In addition to the RTK program, Kolltan has a discovery program exploring TAMs, which has potential applications in cancer, autoimmune and infectious disease.”

According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -4.9% and a 33.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Axsome Therapeutics Inc.

Celldex has an analyst consensus of Strong Buy, with a price target consensus of $14.

OncoSec Medical (NASDAQ: ONCS)

In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $5. The company’s shares opened today at $1.99.

McCarthy observed:

“Next week at the SITC (Society for Immunotherapy of Cancer) Annual Meeting (November 11-13), Oncosec will present data from the phase II study (N=15) evaluating the combination of DNA-based IL-12 and Keytruda in melanoma.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -17.3% and a 21.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Stellar Biotechnologies, and Inovio Pharmaceuticals.

OncoSec Medical has an analyst consensus of Moderate Buy.